Loading…
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Legislative Progress
Introduced
February 16, 2011
Latest Action
February 28, 2011
Primary Sponsor
Jo Ann EmersonRepublican(MO)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
60pct
12d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (7)
2012 · fourth_quarter · Copyright/Patent/Trademark
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements H.R. 4216, Foreign Counterfeit Protection Act: Provisions related to anti-counterfeiting H.R. 6502, Life-Threatening Diseases Compassion through Combination Therapy Act: Provisions related to market exclusivity and expedited review H.R. 6621, a bill to make technical corrections to the America Invents Act H.R. 6654, Foreign Counterfeit Merchandise Prevention Act: Provisions related to trade enforcement S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting S. 3486, Patent Law Treaties Implementation Act of 2012: Patent law treaties S. 3652, Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,120,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Copyright/Patent/Trademark
H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs, provisions relating to authorized generics H.R. 3995 - Protect Consumer Access to Generic Drugs Act, provisions related to patent settlements H.R. 6621 - A bill to make technical corrections to the America Invents Act S. 27 - Preserve Access to Affordable Generics Act, provisions related to patent settlements S. 373 - The Fair Prescription Drug Competition Act, provisions related to authorized generics S. 1882 - Fair and Immediate Release of Generic Drugs Act, provisions related to patent settlements International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $1,370,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Pharmacy
S. 27, Preserve Access to Affordable Generics Act S. 31, Prescription Drug and Health Improvement Act of 2011 S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 147, Prescription Drug Affordability Act H.R. 741, To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1971, Pharmacy Competition and consumer Choice Act of 2011 H.R. 2128, STEAM (Stripping the E-Prescribe Arbitrary Mandates) Act of 2011 S. 1058, Pharmacy Competition and Consumer Act of 2011 S. 1356, Affordable Medicines Utilization Act of 2011 S. 1584, Drug Safety and Accountability Act of 2011 H.R. 3026, Safeguarding America's Pharmaceuticals Act of 2011 S. 2002, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet Pharmacies S. 3187, FDA Safety and Innovation Act
Client expense: $440,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE
2012 · fourth_quarter · Pharmacy
Proposals to limit or restrict direct-to-consumer advertising of pharmaceuticals Proposals to require a moratorium on the advertising of new prescription medicines Proposals to extend the Food and Drug Administration authority for the advertising of over-the-counter medications HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.Res. 343 Disapproving the Supreme Courts decision in Sorrell v. IMS Health Oppose proposals to add overly-burdensome product warnings to DTC advertising
Client expense: $20,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
2012 · fourth_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) S. 2029 (Online Protection and Enforcement of Digital Trade Act) S. 2258 (Songwriters Tax Simplification Reauthorization Act) S. 2269 (Anti-Trust Freedom Act of 2012) S. 3389 (Trade Secrets EEA) S. 3486 (Patent Law Treaties Implementation Act of 2012) S. 3609 (Internet Radio Fairness Act) S. 3642 (Theft of Trade Secrets Clarification Act) S. 3652 (Bill to allow acceleration certificates awarded under the Patents for Humanity program to be transferable) S. Con. Res 50 (Internet governance) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 592 (Sunshine in Litigation Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3261 (Stop Online Piracy Act) H.R. 3375 (Imposing Duties on China for IP Piracy) H.R. 3468 (Counterfeit Drug Penalty Enhancement Act) H.R. 3699 (Research Works Act) H.R. 3782 (Online Protection and Enforcement of Digital Trade Act) H.R. 3889 (Promoting Automotive Repair, Trade, and Sales Act) H.R. 3995 (Protecting Consumer Access to Generic Drugs Act) H.R. 4216 (Foreign Counterfeit Prevention Act) H.R. 6012 (Customs Redaction Bill for Semiconductor Chips) H.R. 6029 (Economic Espionage) H.R. 6215 (Trademark Dilution) H.R. 6245 (Saving High-Tech Innovators from Egregious Legal Disputes Act) H.R. 6353 (Patent Box, Manufacturing American Innovation Act) H.R. 6432 (Patent Law Treaties Implementation Act) H.R. 6480 (Internet Radio Fairness Act) H.R. 6621 (AIA Technical Corrections Bill) H. Con. Res. 42 (The Creativity and Innovation Resolution) H. Con. Res. 127 (Internet Governance)
Client expense: $60,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2012 · third_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3497, MODDERN Cures Act of 2011: Provisions related to data protection H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting S. 3486, Patent Law Treaties Implementation Act of 2012: Patent law treaties Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates [no bill number] Technical changes to America Invents Act [H.R. 1249 and S.23] International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,140,000 · Firm income: Not reported
2012 · third_quarter · Pharmacy
S. 27, Preserve Access to Affordable Generics Act S. 31, Prescription Drug and Health Improvement Act of 2011 S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 147, Prescription Drug Affordability Act H.R. 741, To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1971, Pharmacy Competition and consumer Choice Act of 2011 H.R. 2128, STEAM (Stripping the E-Prescribe Arbitrary Mandates) Act of 2011 S. 1058, Pharmacy Competition and Consumer Act of 2011 S. 1356, Affordable Medicines Utilization Act of 2011 S. 1584, Drug Safety and Accountability Act of 2011 H.R. 3026, Safeguarding America's Pharmaceuticals Act of 2011 S. 2002, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet Pharmacies S. 3187, FDA Safety and Innovation Act
Client expense: $440,000 · Firm income: Not reported
2012 · third_quarter · Pharmacy
Proposals to limit or restrict direct-to-consumer advertising of pharmaceuticals Proposals to require a moratorium on the advertising of new prescription medicines Proposals to extend the Food and Drug Administration authority for the advertising of over-the-counter medications HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.Res. 343 Disapproving the Supreme Courts decision in Sorrell v. IMS Health Oppose proposals to add overly-burdensome product warnings to DTC advertising
Client expense: $20,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
2012 · third_quarter · Copyright/Patent/Trademark
S. 1882 - Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements H.R. 3995 - Protect Consumer Access to Generic Drugs Act - provisions related to patent settlements HR 3497 - MODERN Cures Act of 2011 - provisions related to data protection S.27 - Preserve Access to Affordable Generics Act - provisions related to patent settlements H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions relating to authorized generics H.R. 2182, S.1734 - Generating Antibiotic Incentives Now Act of 2011 - implementation of provisions related to antibiotics and incentives S.373 - The Fair Prescription Drug Competition Act - provisions related to authorized generics S. 1882 - The Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements No bill # assigned - International intellectual property issues No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Technical corrections to the America Invents Act
Client expense: $890,000 · Firm income: Not reported
2012 · third_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) S. 2029 (Online Protection and Enforcement of Digital Trade Act) S. 2258 (Songwriters Tax Simplification Reauthorization Act) S. 2269 (Anti-Trust Freedom Act of 2012) S. 3389 (Trade Secrets EEA) S. 3486 (Patent Law Treaties Implementation Act of 2012) S. Con. Res 50 (Internet governance) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3375 (Imposing Duties on China for IP Piracy) H.R. 3468 (Counterfeit Drug Penalty Enhancement Act) H.R. 3699 (Research Works Act) H.R. 3782 (Online Protection and Enforcement of Digital Trade Act) H.R. 3889 (Promoting Automotive Repair, Trade, and Sales Act) H.R. 3995 (Protecting Consumer Access to Generic Drugs Act) H.R. 4216 (Foreign Counterfeit Prevention Act) H.R. 6012 (Customs Redaction Bill for Semiconductor Chips) H.R. 6029 (Economic Espionage) H.R. 6215 (Trademark Dilution) H.R. 6245 (Saving High-Tech Innovators from Egregious Legal Disputes Act) H.R. 6353 (Patent Box, Manufacturing American Innovation Act) H. Con. Res. 42 (The Creativity and Innovation Resolution) H. Con. Res. 127 (Internet Governance)
2012 · second_quarter · Pharmacy
S. 27, Preserve Access to Affordable Generics Act S. 31, Prescription Drug and Health Improvement Act of 2011 S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R. 147, Prescription Drug Affordability Act H.R. 741, To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1971, Pharmacy Competition and consumer Choice Act of 2011 H.R. 2128, STEAM (Stripping the E-Prescribe Arbitrary Mandates) Act of 2011 S. 1058, Pharmacy Competition and Consumer Act of 2011 S. 1356, Affordable Medicines Utilization Act of 2011 S. 1584, Drug Safety and Accountability Act of 2011 H.R. 3026, Safeguarding America's Pharmaceuticals Act of 2011 S. 2002, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet Pharmacies S. 3187, FDA Safety and Innovation Act
Client expense: $560,000 · Firm income: Not reported
2012 · second_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3497, MODDERN Cures Act of 2011: Provisions related to data protection H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates [no bill number] Technical changes to America Invents Act [H.R. 1249 and S.23] International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,840,000 · Firm income: Not reported
2012 · second_quarter · Pharmacy
Proposals to limit or restrict direct-to-consumer advertising of pharmaceuticals Proposals to require a moratorium on the advertising of new prescription medicines Proposals to extend the Food and Drug Administration authority for the advertising of over-the-counter medications HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.Res. 343 Disapproving the Supreme Courts decision in Sorrell v. IMS Health Oppose proposals to add overly-burdensome product warnings to DTC advertising
Client expense: $20,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Telecommunications & Information Administration (NTIA), SENATE
2012 · first_quarter · Copyright/Patent/Trademark
HR 3995 - Protect Consumers Access to Generic Drugs Act - provisions related to patent settlements S. 1882 - Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements HR 3497 - MODDERN Cures Act of 2011 - provisions related to data protection S 27 - Preserve Access to Affordable Generics Act - provisions related to patent settlements H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions relating to authorized generics HR 3261 - Stop Online Piracy Act - provisions related to anti-counterfeiting S 373 - The Fair Prescription Drug Competition Act - provisions related to authorized generics S 968 - Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 - provisions related to anti-counterfeiting HR 2182,S 1734 - Generating Antibiotic Incentives Now Act of 2011- provisions related to antibiotics and incentives
Client expense: $1,440,000 · Firm income: Not reported
2012 · second_quarter · Copyright/Patent/Trademark
S. 1882 - Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements H.R. 3497 - MODDERN Cures Act of 2011 - provisions related to data protection S. 27 - Preserve Access to Affordable Generics Act - provisions related to patent settlements H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions relating to authorized generics H.R. 2182,S. 1734 - Generating Antibiotic Incentives Now Act of 2011 - provisions related to antibiotics and incentives H.R. 3261 - Stop Online Piracy Act - provisions related to anti-counterfeiting S. 373 - The Fair Prescription Drug Competition Act - provisions related to authorized generics S. 968 - Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 - provisions related to anti-counterfeiting No bill # assigned - International intellectual property issues No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Technical corrections to the America Invents Act
Client expense: $1,220,000 · Firm income: Not reported
2012 · second_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) S. 2029 (Online Protection and Enforcement of Digital Trade Act) S. 2258 (Songwriters Tax Simplification Reauthorization Act) S. 2269 (Anti-Trust Freedom Act of 2012) S. Con. Res 50 (Internet governance) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3375 (Imposing Duties on China for IP Piracy) H.R. 3468 (Counterfeit Drug Penalty Enhancement Act) H.R. 3699 (Research Works Act) H.R. 3782 (Online Protection and Enforcement of Digital Trade Act) H.R. 3889 (Promoting Automotive Repair, Trade, and Sales Act) H.R. 3995 (Protecting Consumer Access to Generic Drugs Act) H.R. 4216 (Foreign Counterfeit Prevention Act) H.R. 6012 (Customs Redaction Bill for Semiconductor Chips) H.R. 6029 (Economic Espionage) H. Con. Res. 42 (The Creativity and Innovation Resolution) H. Con. Res. 127 (Internet Governance)
2012 · first_quarter · Health Issues
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD, value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics,
Client expense: $692,475 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
2012 · first_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3497, MODDERN Cures Act of 2011: Provisions related to data protection H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $5,310,000 · Firm income: Not reported
2012 · first_quarter · Copyright/Patent/Trademark
HR 3995 - Protect Consumers Access to Generic Drugs Act - provisions related to patent settlements S. 1882 - Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements HR 3497 - MODDERN Cures Act of 2011 - provisions related to data protection S 27 - Preserve Access to Affordable Generics Act - provisions related to patent settlements H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions relating to authorized generics HR 3261 - Stop Online Piracy Act - provisions related to anti-counterfeiting S 373 - The Fair Prescription Drug Competition Act - provisions related to authorized generics S 968 - Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 - provisions related to anti-counterfeiting HR 2182,S 1734 - Generating Antibiotic Incentives Now Act of 2011- provisions related to antibiotics and incentives
Client expense: $2,120,000 · Firm income: Not reported
2012 · first_quarter · Pharmacy
Oppose proposals to limit or restrict direct-to-consumer advertising of pharmaceuticals Oppose proposals to require a moratorium on the advertising of new prescription medicines Oppose proposals to extend the Food and Drug Administration authority for the advertising of over-the-counter medications HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - oppose H.Res. 343 Disapproving the Supreme Courts decision in Sorrell v. IMS Health - oppos Oppose proposals to add overly-burdensome product warnings to DTC advertising
Client expense: $20,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · first_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) S. 2029 (Online Protection and Enforcement of Digital Trade Act) S. 2258 (Songwriters Tax Simplification Reauthorization Act) S. 2269 (Anti-Trust Freedom Act of 2012) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3375 (Imposing Duties on China for IP Piracy) H.R. 3468 (Counterfeit Drug Penalty Enhancement Act) H.R. 3699 (Research Works Act) H.R. 3782 (Online Protection and Enforcement of Digital Trade Act) H.R. 3889 (Promoting Automotive Repair, Trade, and Sales Act) H.R. 3995 (Protecting Consumer Access to Generic Drugs Act) H.R. 4216 (Foreign Counterfeit Prevention Act) H. Con. Res. 42 (The Creativity and Innovation Resolution)
2012 · first_quarter · Pharmacy
S.27, Preserve Access to Affordable Generics Act S.31, Prescription Drug and Health Improvement Act of 2011 S.319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.147, Prescription Drug Affordability Act H.R.741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R.979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R.1971, Pharmacy Competition and Consumer Choice Act of 2011 H.R.2128, STEAM (Stripping The E-Prescribe Arbitrary Mandates) Act of 2011 S.1058, Pharmacy Competition and Consumer Act of 2011 S.1356, Affordable Medicines Utilization Act of 2011 S.1584, Drug Safety and Accountability Act of 2011 H.R.3026, Safeguarding America's Pharmaceuticals Act of 2011 S.2002, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet Pharmacies
Client expense: $560,000 · Firm income: Not reported
2011 · third_quarter · Consumer Issues/Safety/Products
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011
Client expense: $3,420,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
2011 · second_quarter · Consumer Issues/Safety/Products
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011
Client expense: $3,610,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
2011 · first_quarter · Consumer Issues/Safety/Products
Importation The Food, Drug and Cosmetic Globalization Act Dextromethorphan Distribution Dextromethorphan Abuse Reduction H.R. 741 - Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373 - Fair Prescription Drug Competition Act, 2011
Client expense: $3,850,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
2011 · fourth_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provision related to authorized generics H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3497, MODDERN Cures Act of 2011: Provisions related to data protection S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,820,000 · Firm income: Not reported
2011 · fourth_quarter · Copyright/Patent/Trademark
S 27 Preserve Access to Affordable Generics Act - provisions related to patent settlements HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs - provisions relating to authorized generics HR 2182,S 1734 Generating Antibiotic Incentives Now Act of 2011 - provisions related to antibiotics and incentives HR 3261 Stop Online Piracy Act - provisions related to anti-counterfeiting S 373 The Fair Prescription Drug Competition Act - provisions related to authorized generics S 968 Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 - provisions related to anti-counterfeiting
Client expense: $1,030,000 · Firm income: Not reported
2011 · fourth_quarter · Health Issues
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
Client expense: $350,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
2011 · third_quarter · Health Issues
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
Client expense: $510,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
2011 · third_quarter · Health Issues
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
Client expense: $350,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
2011 · fourth_quarter · Pharmacy
S.27, Preserve Access to Affordable Generics Act S.31, Prescription Drug and Health Improvement Act of 2011 S.319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.147, Prescription Drug Affordability Act H.R.741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R.979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R.1971, Pharmacy Competition and Consumer Choice Act of 2011 H.R.2128, STEAM (Stripping The E-Prescribe Arbitrary Mandates) Act of 2011 S.1058, Pharmacy Competition and Consumer Act of 2011 S.1356, Affordable Medicines Utilization Act of 2011 S.1584, Drug Safety and Accountability Act of 2011 H.R.3026, Safeguarding America's Pharmaceuticals Act of 2011 S.2002, To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of Internet Pharmacies
Client expense: $380,000 · Firm income: Not reported
2011 · fourth_quarter · Pharmacy
Proposals to limit or restrict direct-to-consumer advertising of pharmaceuticals Proposals to require a moratorium on the advertising of new prescription medicines Proposals to extend the Food and Drug Administration authority for the advertising of over-the-counter medications HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.Res. 343 Disapproving the Supreme Courts decision in Sorrell v. IMS Health
Client expense: $41,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2011 · fourth_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623, H.R. 592 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968, H.R. 3261, S. 2029 (Online Piracy/Rogue Websites legislation) S. 968, H.R. 1540 (Customs Redaction legislation) S. 978, H.R. 3261 (Copyright Streaming bill) S. 1228, H.R. 1540, H.R. 3261 (Combating Military Counterfeits Act) S. 1830 (Protect American Innovation Act of 2011) S. 1866 (AGREE Act) S. 1886, H.R. 3261, H.R. 3468 (Counterfeiting Drug Penalty Enhancement Acts) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608; House Report 112-284 (FY 2012 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 741 (Fair Prescription Drug Competition Act) H.R. 768 (Soldiers Targeted by Offensive Profiteering Act of 2011) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 1166 (No Stolen Trademarks Honored in America Act) H.R. 2511 (Fashion Design Legislation) H.R. 3010 (Federal Regulations Bill Coble) H.R. 3375 (Imposing Duties on China for IP Piracy) H. Con. Res. 42 (The Creativity and Innovation Resolution)
Client expense: $60,000 · Firm income: Not reported
2011 · third_quarter · Pharmacy
Proposals to limit or restrict direct-to-consumer advertising of pharmaceuticals Proposals to require a moratorium on the advertising of new prescriptions medicines Proposals to extend the Food and Drug Administration authority for the advertising of over-the counter medications HR 741 to amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.Res 343 Disapproving the Supreme Court's decision in Sorrell v. IMS Health
Client expense: $41,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2011 · third_quarter · Consumer Issues/Safety/Products
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011
Client expense: $3,360,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
2011 · third_quarter · Copyright/Patent/Trademark
H.R. 243, Patent Lawsuit Reform Act of 2011: Provisions related to false patent marking H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 1056, Patent Continuing Disclosure Act: Provisions related to false patent marking H.R. 1249, America Invents Act: Provisions related to patent reform H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives H.R. 2276, To require the Director of the United States Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes: gene patent study provisions S. 23, America Invents Act: Provisions related to patent reform S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,740,000 · Firm income: Not reported
2011 · third_quarter · Pharmacy
S.27, Preserve Access to Affordable Generics Act S.31, Prescription Drug and Health Improvement Act of 2011 S.319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.147, Prescription Drug Affordability Act H.R.741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R.979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R.1971, Pharmacy Competition and Consumer Choice Act of 2011 H.R.2128, STEAM (Stripping The E-Prescribe Arbitrary Mandates) Act of 2011 S.1058, Pharmacy Competition and Consumer Act of 2011 S.1356, Affordable Medicines Utilization Act of 2011 S.1584, Drug Safety and Accountability Act of 2011 H.R.3026, Safeguarding America's Pharmaceuticals Act of 2011
Client expense: $440,000 · Firm income: Not reported
2011 · third_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968 (PROTECT IP Act) S. 978 (Copyright Streaming bill) S. 1228 (Combating Military Counterfeits Act) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473, H.J. Res. 79, H.R. 2608 (FY 2011 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H.R. 3010 (Federal Regulations Bill Coble) H. Con. Res. 42 (The Creativity and Innovation Resolution)
Client expense: $60,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2011 · third_quarter · Health Issues
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
Client expense: $400,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
2011 · first_quarter · Health Issues
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
Client expense: $445,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
2011 · second_quarter · Health Issues
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute; S. 668 The Health Care Bureaucrats Elimination Act;
Client expense: $315,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
2011 · second_quarter · Pharmacy
Proposals to limit or restrict direct-to-consumer advertising of pharmaceuticals Proposals to require a moratorium on the advertising of new prescription medicines Proposals to extend the Food and Drug Administration authority for the advertising of over-the-counter medications HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs H.Res. 343 Disapproving the Supreme Courts decision in Sorrell v. IMS Health
Client expense: $41,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2011 · second_quarter · Copyright/Patent/Trademark
H.R. 243, Patent Lawsuit Reform Act of 2011: Provisions related to false patent marking H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provision related to authorized generics H.R. 1056, Patent Continuing Disclosure Act: Provisions related to false patent marking H.R. 1249, America Invents Act: Provisions related to patent reform H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 23, America Invents Act: Provisions related to patent reform S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,690,000 · Firm income: Not reported
2011 · second_quarter · Consumer Issues/Safety/Products
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011
Client expense: $3,550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
2011 · second_quarter · Pharmacy
S.27, Preserve Access to Affordable Generics Act S.31, Prescription Drug and Health Improvement Act of 2011 S.319, Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.147, Prescription Drug Affordability Act H.R.741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs H.R.979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R.1971, Pharmacy Competition and Consumer Choice Act of 2011 H.R.2128, STEAM (Stripping The E-Prescribe Arbitrary Mandates) Act of 2011 S.1058, Pharmacy Competition and Consumer Act of 2011
Client expense: $580,000 · Firm income: Not reported
2011 · second_quarter · Copyright/Patent/Trademark
S.23, H.R. 1249, S.139 (America Invents Act) S.27 (Preserve Access to Affordable Generics Act) S. 139 (Equal Access to Tax Planning Act) S.373, H.R. 741 (Fair Prescription Drug Competition Act) S.603, H.R. 1166 (Trademarks Seized by Cuban Government) S. 623 (Sunshine in Litigation Act of 2011) S. 678 (Economic Espionage Act) S. 968 (PROTECT IP Act) S. 978 (Copyright Streaming bill) S. 1228 (Combating Military Counterfeits Act) H.R. 1, H.R. 1362, H.J.Res. 48, H.R. 1363, H.R. 1473 (FY 2011 Budget) H.R. 243 (Rep. Latta's False Patent Marking Bill) H.R. 307 (Seed Availability and Competition Act) H.R. 1056 (Rep. Issa's False Patent Marking Bill) H. Con. Res. 42 (The Creativity and Innovation Resolution)
Client expense: $60,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2011 · first_quarter · Consumer Issues/Safety/Products
Importation The Food, Drug and Cosmetic Globalization Act Dextromethorphan Distribution Dextromethorphan Abuse Reduction H.R. 741 - Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373 - Fair Prescription Drug Competition Act, 2011
Client expense: $3,790,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
2011 · first_quarter · Copyright/Patent/Trademark
H.R. 243, Patent Lawsuit Reform Act of 2011: false patent marking H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generics H.R. 1056, Patent Continuing Disclosure Act: false patent marking H.R. 1249, America Invents Act: reforms of the patent laws S. 23, America Invents Act: reforms of the patent laws and other provisions S. 27, Preserve Access to Affordable Generics Act: patent settlements S. 373, Fair Prescription Drug Competition Act: authorized generics International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,540,000 · Firm income: Not reported
2011 · first_quarter · Health Issues
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
Client expense: $455,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
2011 · first_quarter · Pharmacy
Proposals to limit or restrict direct-to-consumer advertising of pharmaceuticals Proposals to require a moratorium on the advertising of new prescription medicines Proposals to extend the Food and Drug Administration authority for the advertising of over-the-counter medications HR 741 To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs
Client expense: $41,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Client expense: $80,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
Client expense: $60,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $100,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), SENATE
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office